NCT03075670 - A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 7, 2017

Primary Completion Date

December 8, 2017

Study Completion Date

December 8, 2017

Conditions

Congenital Bleeding DisorderHaemophilia B

Interventions

DRUG

N9-GP

A single dose of 50 IU/kg for intravenous (i.v.) injection

DRUG

ALPROLIX®

A single dose of 50 IU/kg for intravenous (i.v.) injection

Trial Locations (12)

Novo Nordisk Investigational Site, Zurich

Novo Nordisk Investigational Site, Berlin

Novo Nordisk Investigational Site, Philadelphia

Novo Nordisk Investigational Site, Hanover

Novo Nordisk Investigational Site, Duisburg

Novo Nordisk Investigational Site, East Lansing

Novo Nordisk Investigational Site, Chicago

Novo Nordisk Investigational Site, Peoria

Novo Nordisk Investigational Site, Mörfelden-Walldorf

Novo Nordisk Investigational Site, Oklahoma City

Novo Nordisk Investigational Site, Phoenix

Novo Nordisk Investigational Site, Rochester